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There is strong evidence that a functionally important
cluster of amino acids is located on the COOH-terminal
portion of the heavy chain of factor Va, between amino
acid residues 680 and 709. To ascertain the importance
of this region for cofactor activity, we have synthesized
five overlapping peptides representing this amino acid
stretch (10 amino acids each, HC1–HC5) and tested them
for inhibition of prothrombinase assembly and function.
Two peptides, HC3 (spanning amino acid region 690 –
699) and HC4 (containing amino acid residues 695–704),
were found to be potent inhibitors of prothrombinase
activity with IC50 values of ⬃12 and ⬃10 M, respectively. The two peptides were unable to interfere with
the binding of factor Va to active site fluorescently labeled Glu-Gly-Arg human factor Xa, and kinetic analyses showed that HC3 and HC4 are competitive inhibitors
of prothrombinase with respect to prothrombin with Ki
values of ⬃6.3 and ⬃5.3 M, respectively. These data
suggest that the peptides inhibit prothrombinase because they interfere with the incorporation of prothrombin into prothrombinase. The shared amino acid
motif between HC3 and HC4 is composed of Asp695-TyrAsp-Tyr-Gln699 (DYDYQ). A pentapeptide with this sequence inhibited both prothrombinase function with an
IC50 of 1.6 M (with a KD for prothrombin of 850 nM), and
activation of factor V by thrombin. Peptides HC3, HC4,
and DYDYQ were also found to interact with immobilized thrombin. A recombinant factor V molecule with
the mutations Asp695 3 Lys, Tyr696 3 Phe, Asp697 3 Lys,
and Tyr698 3 Phe (factor V2K2F) was partially resistant
to activation by thrombin but could be readily activated
by RVV-V activator (factor VaRVV2K2F) and factor Xa
(factor VaXa2K2F). Factor VaRVV2K2F and factor VaXa2K2F
had impaired cofactor activity within prothrombinase
in a system using purified reagents. Our data demonstrate for the first time that amino acid sequence 695–
698 of factor Va heavy chain is important for procofactor
activation and is required for optimum prothrombinase
function. These data provide functional evidence for an
essential and productive contribution of factor Va to the
activity of prothrombinase.
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The prothrombinase complex, which is composed of the nonenzymatic cofactor factor Va, the enzyme, factor Xa, and the
substrate, prothrombin, associated on a cell membrane-surface
in the presence of Ca2⫹ ions, is responsible for ␣-thrombin
formation during blood coagulation (1, 2). The prothrombinase
complex catalyzes the activation of prothrombin ⬃300,000
times more efficiently than factor Xa alone (3). The increase in
the catalytic efficiency of prothrombinase as compared with
factor Xa alone arises from a decrease in the Km and an increase in the kcat of the enzyme (4 –7). The procofactor, factor V,
does not interact with the components of prothrombinase. Proteolytic processing of factor V by thrombin at Arg709, Arg1018,
and Arg1545, resulting in the production of the active cofactor,
factor Va, which consists of a heavy chain (Mr 105,000) and a
light chain (Mr 74,000), is required for the interaction of the
cofactor with the members of prothrombinase (8 –10). In contrast, proteolytic inactivation of factor Va by activated protein
C (APC)1 results in its inactivation because of the inability of
the cleaved cofactor to interact with factor Xa and prothrombin
(11–16).
Earlier data have demonstrated that, although both chains
of factor Va are required for the interaction with factor Xa, only
the heavy chain of the cofactor binds prothrombin (14, 15, 17).
Cleavage of factor Va by APC at Arg506/Arg679 results in a
10-fold decrease in the affinity of the molecule for factor Xa and
the elimination of its interaction with prothrombin (13–16).
Subsequent cleavage at Arg306, which is lipid-dependent, completely abolishes the ability of the cofactor to interact with
factor Xa (12, 13). Prothrombin and thrombin have two distinct
electropositive binding exosites (anion binding exosite I
(ABE-I) and anion binding exosite II (ABE-II)) that are responsible for the functions of the molecules (18 –27). ABE-I has been
involved in binding to thrombomodulin (28), fibrinogen (29),
heparin cofactor II (30), PAR1 (31), and the COOH-terminal
hirudin peptides (32). ABE-II was found to be involved in the
interaction with heparin cofactor II (30), protease nexin (33),
and antithrombin III (30). Although the involvement of ABE-I

1
The abbreviations used are: APC, activated protein C; DFP, diisopropyl fluorophosphate; PS, L-␣-phosphatidylserine; PC, L-␣-phosphatidylcholine; PCPS, small unilamellar phospholipids vesicles composed of
75% L-␣-phosphatidylcholine and 25% L-␣-phosphatidylserine (w/w);
DAPA, dansylarginine-N-(3-ethyl-1,5-pentanediyl)amide; [OG488]EGRhXa, human factor Xa blocked in the active site with glutamylglycinylarginyl chloromethyl ketone labeled with Oregon Green 488; HPLC,
high performance liquid chromatography; LC/MS, liquid chromatography/mass spectrometry; ELISA, enzyme-linked immunosorbent assay;
PVDF, polyvinylidene difluoride; ABE-I, anion binding exosite I; ABEII, anion binding exosite II; factor V2K2F, quadruple mutant, recombinant human factor V with the mutations Asp695 3 Lys, Tyr696 3 Phe,
Asp697 3 Lys, and Tyr698 3 Phe; factor VaIIa2K2F, quadruple mutant
activated with thrombin; factor VaRVV2K2F, quadruple mutant activated
with RVV-V activator; factor VaXa2K2F, quadruple mutant activated
with factor Xa.
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of prothrombin in the productive interaction with factor Va
within prothrombinase has been clearly demonstrated (18 –21,
34), some data also suggested that ABE-II of the molecule is
also involved in the activation of factors V and VIII (22, 23).
Proexosite I of prothrombin, which is present in a low affinity
state on the molecule, is fully exposed following activation and
formation of thrombin, and the affinity for its ligands increases
by ⬃100-fold (21, 27). The procofactor, factor V, was found to
interact with immobilized thrombin through ABE-I but with a
lower affinity than factor Va (18). As a consequence, there has
been no interaction between prothrombin and factor V reported
because the binding sites involved in the interaction between
the two molecules are most likely hidden within their core and
at least one of the two molecules must be activated and expose
a portion or an entire exosite for the binary interaction to occur.
Factor Va is required for the presentation of the substrate
(prothrombin) to the enzyme (factor Xa). There is evidence
suggesting that incorporation of factor Va into prothrombinase
and its interaction with factor Xa and prothrombin, does not
significantly alters the catalytic triad of the enzyme (35–39). As
a consequence, it has been suggested that, upon interaction
with factor Va, factor Xa expresses cryptic exosites for prothrombin, which in turn appear to be largely responsible for the
increase in the catalytic efficiency of the enzyme within prothrombinase (35–38). These latter studies were performed with
specific inhibitors of factor Xa that interact with the enzyme at
precise sites remote from its active site. However, several laboratories have demonstrated that prothrombin and thrombin
bind to the isolated heavy chain of the cofactor in a calciumindependent manner through ABE-I (14, 15, 18 –21, 40).
Although a binding site for factor Xa has been recently identified on the heavy chain of factor Va (41– 43), the specific
site(s) on the heavy chain of the cofactor that interact with
thrombin and prothrombin remain to be identified. Using various proteolytic enzymes, we and others have shown that the
carboxyl-terminal portion of the heavy chain of factor Va (residues 680 –709) is responsible for the interaction of factor Va
with one or both components of prothrombinase (44 – 46). This
amino acid region, which is highly acidic in nature and contains
the tyrosine residues that were previously shown to have the
potential to be involved in both procofactor activation by thrombin as well as cofactor function (47, 48), may possess residues
that are directly involved in the interaction of the cofactor with
positively charged amino acids provided by one of the protein
components of prothrombinase. Further, we have recently demonstrated that a binding site for prothrombin is located on the
last 13 amino acids of the factor Va heavy chain (46). The
present study was undertaken to identify the specific amino
acid residues from the acidic COOH-terminal region of factor
Va heavy chain that are important for cofactor function and the
molecular mechanisms underlying their contribution to prothrombinase function.
EXPERIMENTAL PROCEDURES

Materials, Reagents, and Proteins—Diisopropyl fluorophosphate
(DFP), O-phenylenediamine dihydrochloride, HEPES, Trizma (Tris
base), Coomassie Blue R-250, and factor V-deficient plasma were purchased from Sigma. The secondary anti-mouse and anti-sheep IgG
coupled to peroxidase were from Southern Biotechnology Associates
Inc. (Birmingham, AL). L-␣-Phosphatidylserine (PS) and L-␣-phosphatidylcholine (PC) were from Avanti Polar Lipids (Alabaster, AL). The
chemiluminescent reagent ECL⫹ and heparin-Sepharose were from
Amersham Biosciences. Normal reference plasma and the chromogenic
substrate Spectrozyme-TH were from American Diagnostica Inc.
(Greenwich, CT). The thromboplastin reagent for the clotting assays
was purchased from Organon Teknika Corp. (Durham, NC). Polyethylene glycol (Mr 8000) was purchased from J. T. Baker (Danvers, MA).
The fluorescent thrombin inhibitor dansylarginine-N-(3-ethyl-1,5-pentanediyl)amide (DAPA), N␣-[(acetylthio)acetyl]-Phe-Pro-Arg-thrombin
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coupled to agarose through the active site as described (18), RVV-factor
V activator, human APC, human factor Xa, human thrombin, human
prothrombin, the sheep antifactor V polyclonal antibody, the monoclonal antibody ␣hFV#1 coupled to Sepharose, and human factor Xa
labeled in the active site with Oregon Green 488 ([OG488]EGR-hXa) as
previously described (49), were from Hematologic Technologies Inc.
(Essex Junction, VT). The cDNA for factor V was purchased from
American Type Tissue Collection (ATCC 40515 pMT2-V, Manassas,
VA). The sequence of this cDNA molecule is identical to the cDNA
published by Jenny et al. (50). All restriction enzymes were from New
England Biolabs (Beverly, MA) and all other molecular biology and
tissue culture reagents and media were from Invitrogen or as indicated.
The two monoclonal antibodies to human factor V (against the heavy
and light chains of the cofactor, i.e. ␣HFVHC#17 and ␣HFVLC#9) were
provided by Dr. Kenneth G. Mann (Department of Biochemistry, University of Vermont, Burlington, VT) and have been extensively characterized (51–54). Overlapping peptides from the region 680 –709 as well
as pentapeptide DYDYQ were synthesized in the Biotechnology Core of
the Cleveland Clinic Foundation (Cleveland, OH), purified by high
performance liquid chromatography (HPLC), and characterized by
mass spectrometry as described (42). Human factor V and factor Va
were purified and concentrated using methodologies previously described employing the monoclonal antibody ␣hFV#1 coupled to Sepharose and heparin-Sepharose (42, 55, 56). The cofactor activity of the
factor Va preparations was measured by a clotting assay using factor
V-deficient plasma and standardized to the percentage of control as
described (55). Phospholipids vesicles composed of 75% PC and 25% PS
(referred to as PCPS vesicles throughout this report) were prepared as
previously described (57). The concentration of phospholipids vesicles
was determined by phosphorus assay as described earlier and is given
as the concentration of inorganic phosphate (58).
Determination of Factor V/Va Clotting Activity of the Recombinant
Molecules—Cofactor activity of wild type and mutant molecules was
measured in a clotting assay using factor V-deficient plasma prior and
after activation by thrombin (15 min, 37 °C) and RVV-V activator (2 h,
37 °C) as described (43, 46). The values were standardized to the percentage of control (55). A linear semi-log graph was constructed using
known concentrations of purified factor V (units/ml as a function of
clotting time). The assay end point was determined by visualization of
the fibrin clot. The activity of the factor V/Va solution (units/ml) was
determined by extrapolation from the graph. The concentration of the
recombinant molecules was determined by a recently described ELISA
(43). Finally, the numbers were combined to obtain the specific activity
of the recombinant factor V solutions (units/mg).
Assay Measuring Thrombin Formation—The formation of thrombin
was analyzed using the fluorescent thrombin inhibitor DAPA as described (11, 12, 42, 59) using a PerkinElmer LS-50B Luminescence
Spectrometer (PerkinElmer Life Sciences, Norwalk, CT) with ex ⫽ 280
nm, em ⫽ 550 nm, and a 500-nm long pass filter in the emission beam
(Schott KV-500). The buffer used in all cases was composed of 20 mM
HEPES, 0.15 M NaCl, 5 mM CaCl2, pH 7.4 (HBS(Ca2⫹), “assay buffer”).
In all cases peptides were preincubated with factor Va prior to the assay
as described in the legend to the figures. The final concentration of
factor Va in the mixture was 4 nM with factor Xa at 10 nM, prothrombin
at 350 nM, DAPA at 700 nM, in the presence of PCPS vesicles (10 M).
The initial rate of thrombin formation (nM IIa䡠min⫺1) was calculated as
described (11, 12, 42) during the initial 5–10 s of the reaction. To verify
whether the peptides have any effect on the active site of thrombin,
control experiments were performed as follows. A given peptide (at 100
M) was incubated in the assay buffer containing DAPA (700 nM); the
base line was monitored for 30 s; thrombin (350 nM) was then added to
the mixture, and the fluorescent intensity resulting from the complexation of DAPA with the active site of thrombin was monitored for 60 s.
The slope of the reaction measuring thrombin formation in the presence
of a given peptide during the first 5 s was calculated and compared with
the slope of a reaction obtained in the absence of peptide. It is noteworthy that, under the conditions employed, the thrombin-DAPA interaction occurred rapidly and the calculated slope of the reaction was
sensitive to all parameters used. However, multiple titrations of the
same reaction using various preparations of thrombin and peptide,
demonstrated that the peptides do not have any significant effect on the
capabilities of thrombin to interact with DAPA. All experiments were
performed in triplicates or as indicated. The concentration of each
peptide given in the figures and figure legends is their final concentration in the assay. The data were stored using the software FL WinLab
(PerkinElmer Life Sciences) and further analyzed and plotted with the
software Prizm (GraphPad, San Diego, CA). In some cases the data
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were also analyzed and plotted using DeltaGraph (DeltaPoint,
Monterey, CA).
Fluorescence Anisotropy Measurements—Fluorescence anisotropy of
[OG488]EGR-hXa was measured using a PerkinElmer LS-50B Luminescence Spectrometer in L-format as recently described (42). Anisotropy
measurements were performed in a quartz cuvette under constant
stirring (low) with ex ⫽ 490 nm, em ⫽ 520 nm with a long pass filter
(Schott KV-520) in the emission beam. In all cases, the total addition of
peptide did not exceed 10% of the volume of the reaction. The concentration of peptide given in the text is the final concentration of the
peptide in the assay mixture. The data were stored using the software
FL WinLab (PerkinElmer Life Sciences) and further analyzed and
plotted with the software Prizm (GraphPad). In some cases the data
were also plotted using DeltaGraph (DeltaPoint).
Mutagenesis and Transient Expression of Recombinant Factor V Molecules—A quadruple mutation of factor V, pMT2-FV-Asp695 3 Lys/
Tyr696 3 Phe/Asp697 3 Lys/Tyr698 3 Phe was synthesized by PCRbased method as described recently (43). First, a double mutant FVAsp695 3 Lys/Tyr696 3 Phe was made in a small DNA fragment of the
factor V cDNA. The mutagenic primers for this double mutant fragment
were 5⬘-GAGTGATGCTAAGTTTGATTACC-3⬘ (sense) and 5⬘-GGTAATCAAACTTAGCATCACTC-3⬘ (antisense) (underlined letters indicate
the mismatch), whereas the outer primers were 5⬘-CATGGAGTGACCTTCTCG-3⬘ (sense) and 5⬘-TCATCCAGGAGAACC-3⬘ (antisense). The
amplicon was subcloned in the cloning vector pGEM-T, and the nucleotide sequences were verified by DNA sequencing. The plasmid having
the double mutation was used as template for synthesizing the quadruple mutant. The mutagenic primers in this case were 5⬘-GCTAAGTTTAAGTTCCAGAACAGACTGG-3⬘ (sense) and 5⬘-CCAGTCTGTTCTGGAACTTAAACTTAGC-3⬘ (antisense). The outer primers were the
same sense and antisense outer primers used in the synthesis of first
double mutant. The factor V DNA fragment having all four mutations
was subcloned into pGEM-T vector and sequenced. Finally, the DNA
fragment was removed from the plasmid by digestion with the restriction enzymes Bsu361 and DraIII. Following purification of the insert
from the agarose gel, the factor V insert that possessed the mutations
was re-ligated into the plasmid pMT2-FV, in which the DNA fragment
between the Bsu361 and DraIII restriction sites was removed. The
ligated plasmids were transformed into DH5␣ bacterial competent cells.
Positive ampicillin-resistant clones for pMT2-FV mutants were selected. The correct sequences and orientations of the inserts were established by DNA sequence analysis with factor V-specific primers. The
wild type pMT2-FV and mutant pMT2-FV plasmids were isolated from
the bacterial culture by the QIAfilter plasmid Midi kit (Qiagen Inc.,
Valencia, CA).
Expression of Recombinant Wild Type and Mutant Factor V in Mammalian Cells—COS-7 cells (ATTC, Manassas VA) or COS-7L (Invitrogen) were maintained in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine, and antibiotics
(100 g/ml streptomycin and 100 IU/ml penicillin) in a humidified
atmosphere of 5% CO2 and 95% air at 37 °C.
The purified plasmids pMT2-FV wild type, and pMT2-FV
(695KFKF698) were used to transfect into COS-7L cells as recently described (43). Following transfection, cells were washed twice with serum-free medium and 6 –10 ml of conditioned media VP-SFM supplemented with 4 mM of L-glutamine were added. After 24 and 48 h, the
harvested medium containing recombinant factor V was centrifuged at
4500 rpm at 4 °C to removed insoluble particles. All control media and
solutions containing the recombinant factor V molecules were concentrated using centrifugal ultrafiltration (Centricon YM 30,000) (43). The
activity and integrity of the molecules was verified before and after
thrombin (and/or RVV-V activator) activation by clotting assays using
factor V-deficient plasma and by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) followed by Western blotting using
both monoclonal and polyclonal antibodies. The concentration of the
recombinant molecules was determined by an ELISA recently described
by our laboratory (43). Because of slight differences in time of incubation with the substrate, in every experiment a plasma factor V standard
(serial dilutions of purified plasma factor V) was run and all values
obtained with the recombinant molecules were compared with the
plasma factor V standard values within the same 96-well plate. No
comparison in concentration was made between recombinant molecules
from one plate to another. The determination of the concentration of the
recombinant molecules was performed by averaging the value found for
each sample run in triplicate.
Measurement of Rates of Thrombin Formation in a Prothrombinase
Assay Using Purified Reagents—All factor V species were activated
with thrombin for 15 min at 37 °C, or with RVV-V activator for 2 h at

37 °C as described (43, 46) followed by the addition of DFP. The factor
Va solution was then incubated for an additional 30 min on ice. Control
experiments demonstrated that, under these conditions, no interference
of the DFP with the assay could be observed because DFP is readily
hydrolyzed in aqueous solution. Factor V was also activated by factor
Xa in the presence of phospholipids. Assay mixtures contained PCPS
vesicles (20 M), DAPA (3 M), various concentrations of recombinant
factor Va species, prothrombin (1.4 M), in 20 mM HEPES, 0.15 M NaCl,
5 mM CaCl2, pH 7.4. The assay was conducted as recently described by
measuring thrombin formation by the change in the absorbance of a
chromogenic substrate at 405 nm monitored with a Thermomax microplate reader (Molecular Devices, Sunnyvale, CA) (43). The initial rates
of thrombin generation under the conditions employed were linear, and
in all experiments no more than 10% of prothrombin was consumed
during the initial course of the assay. All data were analyzed with the
software Prizm (GraphPad).
Direct Binding of the Peptides to Thrombin—Thrombin was immobilized onto agarose through the active site as described (18). Peptide
solutions of HC1-HC5, D13R (46), DYDYQ, and P15H (42) were dissolved in water to a given concentration and then diluted in 20 mM
HEPES, 0.1 M NaCl, pH 7.4, in a manner that 400 g was contained in
each starting solution. In control experiments it was determined that
the maximum amount of peptide that could be retained by the thrombin-agarose column was 400 g. Because some of the peptides contain
aromatic amino acid residues, their concentration was also measured
by optical density. Nevertheless, the presence of all peptides including
those that do not contain aromatic amino acids (HC1, HC2, and HC5) in
the void volume or in the fractions representing the elution of the
thrombin-agarose column was verified by LC/MS as detailed below in
the Analytical Facility of Cleveland State University.
Mass Spectrometry Instruments and Conditions—The identity of all
peptides found in the flow-through or the elution of the thrombinagarose column was verified by mass spectrometry. Because the peptides were in a buffer solution, we used LC/MS for their identification.
In this procedure peptides are first separated from the salt content of
the buffer using an HPLC system (HP 1100, HPLC gradient system,
Agilent Technologies, Palo Alto, CA) with a C18 column (1 mm ⫻ 15 cm,
GraceVydac, Hesperia, CA) with buffers A (0.3% acetic acid in water)
and B (0.3% acetic acid in acetonitrile). The elution of the column was
monitored with a Micromass Quatro II ESI-Triple Quadrupole Mass
Spectrometer (Waters, Milford, MA). The data were collected using a
Compaq Professional Work station AP200 (Hewlett-Packard, Palo Alto,
CA) and analyzed by the software MassLynx version 3.3 (Waters).
Gel Electrophoresis and Western Blotting—SDS-PAGE analyses
were performed using 4 –12% gradient gels according to the method of
Laemmli (60). In several experiments, proteins were transferred to
polyvinylidene difluoride (PVDF) membranes according to the method
described by Towbin et al. (61). After transfer to nitrocellulose, factor V
heavy and light chain(s) were detected using the appropriate monoclonal and polyclonal antibodies (43, 51–54). Immunoreactive fragments were visualized with chemiluminescence.
RESULTS

Inhibition of Prothrombinase Function by Synthetic Peptides
from the Carboxyl-terminal Portion of Factor Va Heavy
Chain—There is increasing evidence that region 680 –709 of
the heavy chain of factor Va is important for cofactor activity
(44 – 46). This hirudin-like region containing functionally important tyrosine residues (47, 48) was proposed to provide an
important site for the productive interaction with proexosite I
of prothrombin (20, 21, 34). To explicitly identify the amino acid
residues from this region that are important for cofactor activity, we have synthesized five overlapping peptides (10 amino
acids each) spanning the entire region of interest (HC1–HC5,
Fig. 1). Each synthetic peptide, except the first and the last, has
5 amino acids in common with the preceding and the following
peptide of the series.
Under the conditions employed, two peptides, HC3, and HC4
(spanning amino acid regions 690 – 699 and 695–704 of factor
Va heavy chain, respectively) inhibited prothrombinase when
used at 100 M (Fig. 2A). Fig. 2A also shows a positive control
peptide, D13R, recently shown to interfere with prothrombin
incorporation into prothrombinase (46) and a negative control
peptide, P15H, that has no effect on cofactor activity under the
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FIG. 1. Peptides from amino acid region 680 –709 of factor V.
Overlapping peptides (10 residues each) from the COOH-terminal portion of the heavy chain of human factor Va are shown (amino acid region
680 –709, HC1–HC5). The arginines are identified (bold and underlined). For the easy reading of this report and the identification of the
position of several important amino acids, Lys680 and Arg709 are identified as the beginning and the end, respectively, of the sequence of
interest.

conditions employed (42). Control experiments also demonstrated that the peptides do not interfere with the capability of
thrombin to interact with DAPA (data not shown). All other
peptides from region 680 –709 had no significant effect on prothrombinase activity. Overall, the data also show that amino
acid sequences 680 – 689 and 700 –709, which together represent ⬃67% of the entire amino acid sequence studied, do not
appear to have any major effect on prothrombinase function
under the conditions employed.
A titration of the inhibition of prothrombinase by peptides
HC3 and HC4 is shown in Fig. 2B. The data demonstrated that
HC3 and HC4 inhibit prothrombinase activity with similar
IC50 values of 12 M (Fig. 2B, filled triangles) and 10 M (Fig.
2B, filled circles), respectively. In the presence of 100 M HC3
and HC4, complete inhibition of prothrombinase function was
observed (Fig. 2B). Thus, both peptides show similar inhibitory
potential. A control pentadecapeptide from the middle portion
of the heavy chain of factor Va (P15H, Ref. 42) had no effect on
prothrombinase function at similar concentrations under the
conditions employed (Fig. 2B, filled squares).
We next tested HC3 and HC4 for their ability to interfere
with the fluorescence anisotropy of a preformed complex composed of membrane-bound [OG488]EGR-hXa-human factor Va
as described (42, 43). No significant decrease in the anisotropy
of [OG488]EGR-hXa was detected following incubation of the
preformed complex with increasing concentrations of either
HC3 or HC4, even in the presence of high concentrations of
peptide (300 M, data not shown). The data demonstrate that
peptides HC3 and HC4 do not interfere with the high affinity
interaction between factor Va and factor Xa on the membrane
surface. The peptides must thus impair another function of the
cofactor within prothrombinase.
The mechanism of inhibition of prothrombinase by the hirudin-like peptides HC3 and HC4 was addressed by investigating
the effect of the peptides on the kinetic parameters of the
enzymatic complex (Km and Vmax). For the sake of simplicity,
only the results obtained with HC4 are shown (Fig. 2C). The
data demonstrated that under the conditions employed and in
the presence of increasing concentrations of peptide, all reactions tend toward the same asymptotic value, which is the Vmax
of the reaction. The calculated values of the Vmax of prothrombinase remained approximately unchanged (⬃960 ⫾ 27 nM
IIa/min), whereas the K0.5 of the enzymatic reactions increased.
These results suggest a competitive type of inhibition (see Refs.
62– 64). Examination of the data shown in Fig. 2C demonstrated a sigmoidal shape of the graphs, which became more
pronounced as the concentration of HC4 was increased (from
0.5 M (filled circles) to 2 M (filled triangles)). These data
represent a competitive inhibition mechanism, where only free
substrate (prothrombin) can produce thrombin in the presence
of prothrombinase (62). According to this model, HC4 binds
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prothrombin in competition with the binding of prothrombin to
prothrombinase (membrane-bound factor Va-factor Xa) (62).
The Ki of prothrombinase inhibition by HC3 obtained from the
value of the IC50 derived from Fig. 2B using the value of the Km
(0.4 M) determined in Fig. 2C (filled squares) was 6.3 M,
whereas the Ki for prothrombinase inhibition by HC4 was
determined to be 5.3 M. These values represent the KD of HC3
and HC4 for their interaction with prothrombin. A similar
inhibition pattern of prothrombinase function was observed by
Anderson et al. (21) who used a peptide containing twelve
amino acids from the COOH-terminal tail of hirudin. Interestingly, the peptide, which has an amino acid composition similar
to HC3 and HC4, with multiple acidic amino acids and a
tyrosine, inhibited prothrombinase with a Ki of 3 M. Overall
the data demonstrate that the hirudin-like peptides HC3 and
HC4 do not interfere with the binding of factor Va to factor Xa
but rather impair prothrombinase activity by inhibiting the
direct interaction of the cofactor with prothrombin. An interference of the peptides with the membrane binding properties
of the cofactor must be excluded, because we and others have
demonstrated that a factor Va molecule lacking a portion or the
entire acidic COOH-terminal peptide from the heavy chain
binds to the lipid bilayer with affinity similar to that of the
purified intact plasma cofactor (44 – 46).
Function of the Amino Acid Sequence Common to HC3 and
HC4 —The common amino acid motif between HC3 and HC4
consists of amino acid residues Asp695-Tyr-Asp-Tyr-Gln699
(DYDYQ) (50). A peptide with this sequence was found to be a
potent inhibitor of prothrombinase function with an IC50 of 1.6
M (Fig. 3A). Complete inhibition of prothrombinase by the
pentapeptide occurred at 40 M. Kinetic analyses of prothrombinase inhibition by DYDYQ similar to the analyses described
for HC4 and shown in Fig. 2C revealed similar sigmoidal tracings in the presence of increasing concentrations of inhibitor
(Fig. 3B). The sigmoidal nature of the curves and the K0.5
increased with increasing inhibitor concentration (100 nM
(filled circles) to 500 nM (open squares)) while the Vmax of the
reaction remained approximately unchanged. Under the conditions employed, the Ki for inhibition of prothrombinase by the
pentapeptide, which is the KD for its interaction with prothrombin, was determined to be 850 nM. The data suggest that
the hirudin-like amino acid motif Tyr695–Gln699 from the
COOH-terminal portion of the heavy chain of factor Va represents a binding site for prothrombin within prothrombinase.
Our results verify the data found with HC4 and are consistent
with the kinetic model of inhibition of prothrombinase shown
in Scheme I. According to this model, the true inhibitor of the
enzymatic reaction is the prothrombin-DYDYQ complex, which
competes with free prothrombin for binding to prothrombinase
(62).
Because peptide DYDYQ is composed of acidic amino acids
and most likely interacts with the positively charged amino
acids from ABE-I of prothrombin as previously suggested (20,
21, 34), it is possible that the peptide also binds to thrombin
and inhibits activation of factor V. We have thus preincubated
thrombin with 100 M pentapeptide and tested the capacity of
the mixture to activate single-chain plasma factor V. Under the
conditions employed, the pentapeptide is a potent inhibitor of
factor V activation by thrombin (Fig. 4, lanes 2–7) because it
impairs cleavage at Arg709 (Fig. 4B), which is the first required
step during the sequential activation of human factor V (8 –10,
50). It is noteworthy that a delay in cleavage at Arg709 and
generation of the heavy chain of the cofactor by the pentapeptide was observed with highly purified, single-chain factor V
only. When using partially activated preparations of factor V,
no delay in the generation of the heavy chain in the presence of
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FIG. 2. Inhibition of prothrombinase function. Panel A, inhibition of
thrombin formation by the peptides. Peptides were incubated with factor Va as
described under “Experimental Procedures” at a fixed concentration (100 M).
The percentage of factor Va cofactor activity was calculated by comparing the activity of prothrombinase in the presence of a
given peptide with the activity of prothrombinase determined in a control reaction in the absence of peptide and in the
presence of factor Xa. The amino acid sequence and identification of each peptide
are given in Fig. 1. The data represent the
average of the results found in three independent measurements. The control
peptide represents a pentadecapeptide
from the middle portion of factor Va
heavy chain (P15H; Ref. 42). D13R is a
peptide recently shown to interfere with
the factor Va-prothrombin interaction
(46). Panel B, titration of HC3 and HC4.
Increasing concentrations of HC3 (filled
triangles), HC4 (filled circles), and P15H
(filled squares) were preincubated with
factor Va and assayed for prothrombinase
activity as described under “Experimental Procedures.” HC3 represents amino
acid sequence 690 – 699 of factor Va heavy
chain; HC4 contains sequence 695–704 of
human factor Va heavy chain; P15H represents amino acid sequence 337–351
from the middle portion of human factor
Va heavy chain (42). The data represent
the average of the results found in three
independent experiments. The concentration of each peptide given on the x axis
represents its final concentration in the
prothrombinase mixture. Panel C, kinetic
analyses of prothrombin activation in the
presence of HC4. The data are plotted as
V0 (initial velocity, in arbitrary units) as a
function of increasing prothrombin concentration in the presence of increasing
concentrations of HC4. The lines drawn
represent the best fit through the points
with an R2 of 0.99. The concentrations of
HC4 used in the experiments are as follows: control, no peptide (filled squares),
0.5 M peptide (filled circles), 1 M peptide (filled inverted triangles), 1.5 M peptide (filled diamonds), and 2 M peptide
(filled triangles). The data represent the
average of the results found in three independent experiments. The apparent inhibition constant (Ki) reported in the text
is the value calculated from the formula:
IC50 ⫽ Ki(1 ⫹ S0/Km) (62), where Km is the
Michaelis-Menten constant of the reaction in the absence of inhibitor (0.4 M),
S0 is the concentration of prothrombin
used (350 nM), and IC50 is the half-maximal inhibition of prothrombinase by HC4
(panel B, 10 M).
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FIG. 3. The effect of peptide DYDYQ
on factor Va function. Panel A, titration of prothrombinase activity in the
presence of increasing concentrations of
peptide DYDYQ. Increasing concentrations of DYDYQ (filled squares) were preincubated with factor Va and assayed for
prothrombinase activity as described under “Experimental Procedures” and in the
legend to Fig. 2. The inset shows the progress of the reaction in the presence of
0 –5 M pentapeptide and allows for a
more precise calculation of the IC50 for
prothrombinase inhibition, which in turn
is necessary for the calculation of the Ki of
the pentapeptide. The latter number represents KD of the inhibitor for its interaction with prothrombin (see Scheme I and
Ref. 62). The data represent the average
of the results found in three independent
experiments. The concentration of peptide given on the x axis represents its final
concentration in the prothrombinase mixture. Panel B, kinetics of inhibition of prothrombinase by peptide DYDYQ. The
data are plotted as V0 (initial velocity, in
arbitrary units) as a function of increasing prothrombin concentration in the
presence of increasing concentrations of
peptide DYDYQ. The lines drawn represent the best fit through the points with
an R2 of 0.99. The concentrations of DYDYQ used in the experiments are as follows: control, no peptide (filled squares),
100 nM peptide (filled circles), 200 nM peptide (filled inverted triangles), 300 nM
peptide (filled diamonds), 400 nM peptide
(filled triangles), and 500 nM peptide
(open squares). The data represent the average of the results found in three independent experiments. The apparent inhibition constant (Ki) reported in the text
was calculated as described in the legend
to Fig. 2C using an IC50 of 1.6 M (Fig.
3A). The kinetic constants calculated
from the data presented in this graph
were used in Scheme I.

SCHEME I. Kinetic model for inhibition of prothrombinase. Activation of prothrombin by prothrombinase is a multistep pathway (3–7). The
initial bimolecular interaction responsible for enzyme formation on the membrane surface (L), is mediated by exosites from factor Va and factor
Xa optimally exposed upon their interaction with the lipid surface. This complex interacts with membrane-bound prothrombin (KS) followed by
docking of the scissile bonds in the active site of prothrombinase (KS*). The last step of the reaction results in thrombin formation. The inhibitor
(DYDYQ) interacts with prothrombin (KD ⬃ 0.85 M) in competition with the binding of prothrombin to prothrombinase (KS ⬃ 0.4 M) (62).
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FIG. 4. The effect of peptide DYDYQ on factor V activation. Panel A, activation of factor V by thrombin alone. Factor V (250 nM) was
incubated with thrombin (1 nM). Panel B, thrombin (1 nM) was preincubated with 100 M peptide DYDYQ and the mixture was added to factor V
(250 nM). At selected time intervals, aliquots of the mixtures were removed, mixed with 2% SDS, heated for 5 min at 90 °C, and analyzed on a
4 –12% SDS-PAGE followed by immunoblotting. Fragments were identified following staining with monoclonal antibody ␣HFV#17, which
recognizes an epitope between amino acid residues 307–506 of factor V and chemiluminescence as described previously (51–54). Lane 1 in panels
A and B depicts aliquots of the mixture withdrawn from the reaction before the addition of thrombin or thrombin/peptide mixture, whereas lanes
2–7 show aliquots of the reaction mixture withdrawn at 30 s, 1 min, 3 min, 5 min, 10 min, and 15 min following the addition of thrombin alone
or of thrombin/peptide mixture. The time of incubation is shown at the bottom of the figure. Position of the molecular size markers is indicated at
left.

the pentapeptide was observed. In contrast, using these latter
preparations, a slower disappearance of the single chain factor
V molecule was apparent (data not shown). These data suggest
that the pentapeptide impairs cleavage at Arg709 on the intact
procofactor only. These data also suggest that other exosites for
thrombin may be available on the factor V molecule as suggested (18 –21). These exosites appear to be involved in cleavage at Arg709 by thrombin, albeit less efficiently. Overall the
data depicted in Figs. 3 and 4 together with the data shown in
Fig. 2 demonstrate that the acidic amino acid stretch Asp695–
Gln699 located at the carboxyl-terminal part of the factor Va
heavy chain appears to have a dual function; it provides an
exosite for prothrombin docking within prothrombinase, and it
also serves as an interactive site for thrombin necessary for
optimum rates of cleavage at Arg709 and activation of the
procofactor. These results are in complete agreement with data
on record demonstrating inhibition of factor V activation by
thrombin by the hirudin-derived peptide, hirudin54 – 65 (18).
Direct Interaction of Hirudin-like Peptides from Factor Va
Heavy Chain with Thrombin-Agarose—To ascertain that the
peptides identified thus far to be inhibitory of prothrombinase
activity contain a binding site for thrombin, the interaction of
all peptides with active site-immobilized thrombin was studied
in chromatographic experiments and is shown in Fig. 5. The
control peptide, P15H (42), did not interact with thrombin, as
demonstrated by its elution in the void volume of the thrombinagarose column (Fig. 5, filled diamonds). All other peptides
containing the hirudin-like motif DYDYQ were eluted from the
column with high salt buffer (Fig. 5, HC3 (filled squares), HC4
(filled triangles), and DYDYQ (filled circles)). Two other peptides that could not be identified by the absorbance at 280 nm
because they do not contain aromatic amino acids, but containing acidic amino acids and having the potential to interact with
ABE-I or ABE-II of thrombin (HC1 and HC2, Fig. 1), were
present in the flow-through of the thrombin-agarose column
and detected by LC/MS (Fig. 5, inset, panels A and B). Fig. 5C
shows that peptide HC5 containing amino acid residues 700 –
709 does not interact with thrombin-agarose. The data demon-

strate that not any randomly selected acidic amino acid sequence can interfere with the binding of factor Va to the anionic
binding exosite(s) of thrombin and strongly suggest that amino
acid sequence Asp695–Gln699 contained in three of the seven
peptides tested is a specific amino acid motif, which represents
a binding site for thrombin.
Expression and Activation of Recombinant Human Factor V
Molecules—In view of all these findings, we used recombinant
technology to assess the contribution of 4 of the 5 amino acid
residues identified above on both factor V activation and factor
Va cofactor function. Two charge reversal and two conservative
mutations were introduced into sequence 695– 698 of factor V.
We have thus prepared a quadruple mutant factor V molecule
with the mutations Asp695 3 Lys, Tyr696 3 Phe, Asp697 3 Lys,
and Tyr698 3 Phe (factor V2K2F). Recombinant wild type factor
V and factor V2K2F were expressed in COS-7L cells, and their
concentrations were determined using the ELISA recently developed in our laboratory (43).
The recombinant molecules were first screened for clotting
activity and the results are shown in Table I. Wild type factor
V had a specific activity of 145 units/mg. Activation of the wild
type molecule by thrombin or RVV-V activator resulted in
cofactors with similar clotting activities (497 and 570 units/mg,
respectively; Table I). The quadruple mutant (factor V2K2F) was
unable to promote clotting under the conditions employed. Factor V2K2F was also unable to promote clotting following activation by thrombin (factor VaIIa2K2F) and/or RVV-V activator
(factor VaRVV2K2F). The two cofactor molecules had an activity
analogous to the activity of the media collected from mocktransfected cells (⬍0.2% of the clotting activity of the wild type
molecules activated under similar conditions; Table I). These
data demonstrate that, once activated, factor VaIIa2K2F and
factor VaRVV2K2F are deficient in their clotting activity.
We next investigated the ability of the recombinant molecules to be assembled into prothrombinase using an assay
employing purified reagents and a chromogenic substrate that
measures thrombin generation. Because the assay is conducted
with limiting factor Va concentrations (0.5 nM), any intrinsic
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FIG. 5. Direct interaction of hirudin-like peptides from the COOH terminus of factor Va heavy chain with thrombin-agarose. Small
scale chromatography of hirudin-like peptides was performed on a 2.5-ml thrombin-agarose as described (18). Each run represents 400 g of
peptide. This amount of peptide was determined to saturate the specific sites of thrombin of the column used (2.5 ml). Elution was performed with
2 M NaCl and was started at the point indicated by the arrow (fraction 30). The presence of the peptides in the corresponding fractions was
monitored by absorbance at 280 nm (shown on the y axis) and by LC/MS (inset). Results show HC3 (filled squares), HC4 (filled triangles), DYDYQ
(filled circles), and P15H (filled diamonds) monitored by the absorbance at 280 nm. Inset, mass spectrometry analysis of the peptides that could
not be monitored by absorbance at 280 nm (i.e. HC1, HC2, and HC5). These peptides were treated similarly to all other peptides and fractions of
similar size were collected. Aliquots from fractions 7 and 35 from each separate experiment were submitted to LC/MS analysis as described under
“Experimental Procedures” (depicted by the hatched arrows at the bottom of the chromatogram). The results from tube 7 from three chromatograms
are depicted. The data are presented as percentage of intensity of the signal as a function of the mass of the peptide divided by the charge (m/z).
Inset panel A, HC1 (Mr(calculated) ⫽ 1268); inset panel B, HC2 (Mr(calculated) ⫽ 1132); inset panel C, HC5 (Mr(calculated) ⫽ 1053). The spectrum of HC1
has two major peaks: at 635.5 and at 424, and one minor peak at 1270 (⬃1268 ⫹ 1). The peak at 635.5 represents the peptide (mass/charge) with
two positive charges ([M ⫹ 2H]⫹) i.e. [(1268 ⫹ 2 ⫽ 1270)]/2 ⫽ 635, whereas the peak at 424 represents HC1 with three positive charges ([M ⫹ 3H]2⫹)
i.e. [(1268 ⫹ 3 ⫽ 1271)]/3 ⫽ 424. Inset panel B shows HC2 with one positive charge (1132 ⫹ 1 ⫽ 1133). HC5 spectrum has two major peaks: one
at 528 and one at 352. The peak at 528 represents the peptide with two positive charges ([M ⫹ 2H]⫹) i.e. [(1053 ⫹ 2 ⫽ 1055)]/2 ⫽ 527.5, whereas
the other peak represents HC5 with three positive charges ([M ⫹ 3H]2⫹) i.e. [(1053 ⫹ 3 ⫽ 1056)]/3 ⫽ 352. The minor peak at 1054 represents the
peptide with one positive charge. It is noteworthy that, in gas phase, the number of protons attached to each peptide depends on the number
(quantity) of basic residues contained in each peptide. HC1 contains 1 lysine and 1 arginine, HC2 does not contain any basic residues, whereas HC5
has 2 arginines (see Fig. 1). Thus, HC1 and HC5 are more likely to bind two or three protons than HC2. Consequently the molecule with one proton
is the major species observed in the mass spectrum of HC2 (inset panel B).
TABLE I
Clotting activity of various recombinant factor V species
Wild type and mutant factor V molecules were assayed for clotting
activity as described under “Experimental Procedures.”
Factor V speciesa

Clotting time

Activity

Specific activity

s

units/ml

units/mg

Media from mock
transfected cells
Wild type FV
Wild type FVIIa
Wild type FVRVV
Factor V2K2F
Factor VaIIa2K2F
Factor VaRVV2K2F

67.6 ⫾ 1.1
0.12
0.44
0.47
0.0046
0.0042
0.002

145
497
570
5.6
5.1
2.4

32.1 ⫾ 1.2
20.5 ⫾ 0.6
18.8 ⫾ 0.5
66.7 ⫾ 1.3
68.7 ⫾ 4.8
73.1 ⫾ 4

a
All factor V species were assayed for clotting activity at 2.5 nM.
Factor VaIIa, wild type factor V activated with thrombin; factor VaRVV,
wild type factor V activated with RVV.

deficiency in the activity of the complex reflects the inability of
the recombinant mutant molecule to act as a cofactor in prothrombinase. Fig. 6A shows the results obtained following incubation of the procofactors with thrombin. The data demonstrate that the wild type recombinant factor Va molecule
displays normal cofactor activity (⬃1800 mOD/min, filled
squares) under the conditions employed and is composed of
heavy and light chains (Fig. 6A, inset, lane 1). Under similar
experimental conditions, factor V2K2F activation by thrombin
was impaired. The inset in Fig. 6A (lane 2) shows that, although there was some generation of heavy and light chains of

mutant factor Va following a 15-min incubation with thrombin,
considerable amounts of high molecular weight material remained on top of the gel. Furthermore, the factor V2K2F/
VaIIa2K2F mixture had no cofactor activity when compared with
the wild type factor Va molecule (ⱕ20 mOD/min); its cofactor
activity was similar to the activity of factor Xa alone. The
activity of the factor V2K2F/VaIIa2K2F solution within prothrombinase remained essentially the same even when 10 and 50
times more total protein was used (Fig. 6A, 5 nM (filled inverse
triangles) and 25 nM (filled diamonds)). The slow increase in
the activity of the factor V2K2F/VaIIa2K2F solution after 2 min of
incubation in the reaction mixture is a consequence of the slow
activation of the molecule during the course of the assay by
factor Xa and confirms that the mutant procofactor cannot be
efficiently activated by thrombin. Slow activation of factor V
during the course of the prothrombinase assay by factor Xa
and/or thrombin generated in situ was previously observed
when studying prothrombinase activity in the presence of unactivated factor V (12, 65).
The results shown in Fig. 6 (B and C) demonstrate that
activation of the wild type molecule by RVV-V activator (Fig.
6B, filled squares) or by factor Xa (65) (Fig. 6C, filled squares)
results in cofactors with activities similar to those of the thrombin-activated molecule (Fig. 6A, filled squares). However, under similar experimental conditions, factor VaRVV2K2F and factor VaXa2K2F have similar but still impaired cofactor activities
within prothrombinase (Fig. 6, B (filled triangles) and C (filled
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FIG. 6. Comparison of cofactor activities of recombinant factor V molecules following activation by thrombin, RVV-V activator, and factor Xa. The cofactor activities of various recombinant factor Va molecules were measured in an assay system using purified
reagents and employing Spectrozyme-TH to probe for thrombin generation as previously described (43) and detailed under “Experimental
Procedures.” Initial rates of prothrombin activation were determined at ambient temperature in the presence of 5 nM factor Xa. Panel A,
activation by thrombin. The factor V species were activated by thrombin (10 nM, 15 min at 37 °C). The subunit composition of the thrombin
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triangles)). Prothrombinase activity does not increase with increasing cofactor concentration (Fig. 6, B (filled diamonds) and
C (filled inverse triangles)). Although the activity of these cofactors within prothrombinase is ⬃6-fold higher than the cofactor activity obtained with the thrombin activated solution of
factor V2K2F/VaIIa2K2F, factors VaRVV2K2F and VaXa2K2F have
⬃22-fold less cofactor activity than the wild type molecule
activated under similar experimental conditions. It is noteworthy that prolonged incubation of factor V2K2F with thrombin
resulted in a cofactor molecule (factor VaIIa2K2F) composed of
heavy and light chains with activity similar to that for factors
VaRVV2K2F and VaXa2K2F (data not shown). Altogether the data
shown in Fig. 6 demonstrate that: 1) factor V2K2F is impaired in
its activation by thrombin, and 2) the activated mutant cofactor
molecules (factor VaRVV2K2F and factor VaXa2K2F) are impaired
in their intrinsic function within prothrombinase, most likely
because of impaired interaction with prothrombin. These data
underline the importance of amino acid region Asp695–Tyr698
from factor V and verify a previously postulated hypothesis
suggesting that the binding site for thrombin responsible for
facilitating cleavage at Arg709 of factor V may also be involved
in the interaction of factor Va with the substrate of prothrombinase, thus regulating prothrombin activation (19).
DISCUSSION

In the present report, we have shown that amino acids 695–
698 of factor Va heavy chain are crucial for both factor Va
cofactor activity and cleavage of factor V by thrombin at Arg709
and activation. These 4 amino acids are part of the acidic
COOH-terminal portion of factor Va heavy chain (amino acid
residues 680 –709). This entire sequence is not conserved
among species, with only 7 amino acids being identical (7/30⬃
23%) (50, 66 – 68). By mutating residues 695– 698, we have
obtained a recombinant factor V molecule, which is impaired in
its activation by thrombin and is deficient in its clotting activity. This molecule has also impaired cofactor activity in a prothrombinase assay using purified reagents and saturating concentrations of factor Xa. It is remarkable that we obtained such
a dramatic effect on both factor V activation and cofactor function, by merely changing 4 amino acids among the 2196 residues in factor V. However, a similar dramatic reduction of
clotting and intrinsic tenase activity as well as a decrease in
thrombin cleavage efficiency were observed when several important tyrosine residues adjacent to thrombin-activating
cleavage sites were mutated to phenylalanine in recombinant
human factor VIII (69). Further, as in the present study, the
level of decrease in cofactor activity when using purified re-
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agents did not match the considerable loss in clotting activity
(69). Earlier data also demonstrated that: 1) factor V sulfation
at several tyrosine residues located at the carboxyl-terminal
portion of its heavy chain is required for both activation of the
procofactor by thrombin and full procoagulant activity of factor
Va (47, 48), and 2) several non-homologous peptides corresponding to amino acid sequences from natural thrombin inhibitors and substrates were found to inhibit thrombin activity
without blocking its active site because of an interaction with a
specific exosite of the enzyme (70 –73). The common theme
between all these findings, which is also illustrated by our
data, was an acidic amino acid sequence containing the amino
acid motif Asp-Tyr that is required for tyrosyl-sulfotransferases (72). Additionally, sulfation of specific hirudin-derived
peptides on tyrosine residues, adjacent to acidic amino acids,
resulted in a significant increase in the affinity of the peptides
for ABE-I of thrombin (20, 21, 74). In fact, the acidic region
preceding Tyr696 and Tyr698 in factor V satisfies all the criteria
for sulfation and may be required for proper attachment and
function of tyrosyl sulfotransferases (72, 75–77). Thus, the
amino acid motif DYDYQ described herein appears to be a good
substrate for sulfation and can also mediate a productive interaction with ABE-I of thrombin as previously suggested (20,
21, 47, 48). It is important to note that, although the amino acid
motif DYQ is conserved among species, the preceding 2 amino
acids of this sequence vary considerably among them (50, 66 –
78). Because it has been shown that there is a difference in
prothrombinase efficiency when mixing bovine prothrombin
with human prothrombinase as compared with activation of
human prothrombin by human prothrombinase (21), we can
speculate that, although the amino acid sequence DYDYQ of
human factor Va provides a binding site for the human prothrombin molecule, the first 2 amino acids of this motif may be
required for species specificity recognition. However, it must be
also noted that the possibility that region DYDYQ of the cofactor modulates a remote portion of factor Va, which in turn is
responsible for the interaction of factor Va with thrombin and
prothrombin, cannot be excluded by our findings.
We have shown that a 42-amino acid peptide (N42R) from
the middle portion of the factor Va heavy chain (representing
residues 307–351 of factor V) produces a cofactor effect on
factor Xa, increasing the catalytic efficiency of the enzyme by
severalfold. Similarly, a 9-amino acid peptide (AP4⬘, residues
323–331) and a 5-amino acid peptide (E5A, residues 323–327)
from N42R also generated a cofactor effect when incubated
with factor Xa alone. Nonetheless, the effect of all these pep-

activated species was also analyzed on a 4 –12% SDS-PAGE, followed by transfer to PVDF membranes and immunostaining with monoclonal
antibodies ␣HFVHC#17 and ␣HFVLC#9 (inset). Lane 1, wild type factor V following the incubation with thrombin; lane 2, factor V2K2F following
incubation with thrombin under similar experimental conditions. The cofactor activities of various factor Va species are depicted as follows: filled
squares, wild type recombinant factor Va (0.5 nM); filled triangles, factor V2K2F/Va2K2F solution (0.5 nM); filled inverted triangles, factor
V2K2F/Va2K2F solution (5 nM); filled diamonds, factor V2K2F/Va2K2F solution (25 nM). The data represent the average of the results found in three
independent experiments. HC and LC represent the heavy (Mr 105,000) and light (Mr 74,000) chains of the cofactor, respectively. Panel B,
activation by RVV-V activator. The recombinant factor V species were activated with RVV-V activator (6 nM, 2 h at 37 °C) as recently described
(46). The subunit composition of the RVV-activated species was also analyzed on a 4 –12% SDS-PAGE after reduction with 2% ␤-mercaptoethanol
followed by transfer to PVDF membranes and immunostaining with monoclonal antibodies ␣HFVHC#17 and ␣HFVLC#9 (inset). Lane 1, wild type
factor V following incubation with RVV; lane 2, factor V2K2F following incubation with RVV. The cofactor activities of various recombinant factor
Va species are depicted as follows: filled squares, wild type recombinant factor Va (0.5 nM); filled triangles, factor VaRVV2K2F (0.5 nM); filled
diamonds, factor VaRVV2K2F (25 nM). The data represent the average of the results found in two independent experiments. HC and LC represent
the heavy (Mr 150,000) and light (Mr 74,000) chains of the RVV-activated cofactors, respectively. Panel C, activation by factor Xa. The factor V
species were activated with factor Xa (5 nM, 20 min in the presence of 20 M PCPS vesicles at 37 °C) as described (65). The amount of factor Xa
brought in the assay from the activation mixtures was accounted for in the calculation of the final concentration of factor Xa (5 nM final
concentration). The subunit composition of the factor Xa-activated species was also analyzed on a 4 –12% SDS-PAGE after reduction with 2%
␤-mercaptoethanol, followed by transfer to PVDF membranes and immunostaining with monoclonal antibodies ␣HFVHC#17 and ␣HFVLC#9 (inset).
The cofactor activities of various factor Va species are depicted as follows: filled squares, wild type recombinant factor Va (0.5 nM); filled triangles,
factor VaXa2K2F (0.5 nM); filled inverted triangles, factor VaXa2K2F (5 nM). The data represent the average of the results found in three independent
experiments. HC represents the heavy chain (Mr 150,000) of the factor Xa-activated cofactors. Upon prolonged exposure of the immunoblots, the
Mr 105,000 heavy chain of the cofactor was also apparent. In all insets, the mutant molecules were consistently overloaded on the gels to identify
any abnormal fragments and/or migration.
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tides on the enzyme was not as pronounced as with intact
factor Va (41– 43). All these peptides contain a portion or the
entire binding site of factor Va heavy chain for factor Xa. Thus,
binding of the cofactor or of its isolated binding domains to
factor Xa most likely results in the exposure of specific binding
exosites on the enzyme necessary for prothrombin docking as
suggested (35–38, 49, 78). However, the magnitude of the effect
observed on factor Xa was severalfold smaller in the presence of
the peptides when compared with the effect produced by the
entire factor Va molecule. Although the extent of the cofactor
effect on factor Xa may be dependent on the size of the molecule
and/or the multiple points of contact from factor Va that participate to the binding to the enzyme, it is also possible that
expression of the hidden exosite for prothrombin on factor Xa
may not be enough alone to account for the dramatic increase
in the catalytic efficiency of factor Xa within prothrombinase
when compared with factor Xa alone.
Although the critical role of factor Va for timely and specific
prothrombin activation by prothrombinase has been long established, the molecular mechanism by which factor Va accelerates the catalytic efficiency of factor Xa upon prothrombinase
assembly remains an enigma. Several studies based on experiments using either inhibitors of prothrombinase that interact
with factor Xa at sites remote from its active site or active
site-inhibited thrombin have offered a litany of arguments in
favor of the hypothesis that incorporation of factor Va into
prothrombinase only results in the exposure of cryptic exosites
on factor Xa that facilitate its interaction with prothrombin.
Because complete inhibition of prothrombinase occurred when
using these competitive inhibitors without any interference
with the active site of the enzyme, it was also concluded that
the exposed cryptic exosites on factor Xa alone, following its
interaction with factor Va, may also account for the substrate
specificity of prothrombinase (35–38, 49, 78). However, several
laboratories have independently demonstrated that factor Va
heavy chain interacts directly with prothrombin through
ABE-I and probably ABE-II (14, 15, 18 –23, 34, 79). These latter
conclusions are also supported by the fact that no interaction
between bovine prothrombin and factor Xa could be detected in
the absence of factor Va (80). A direct interaction between
factor Va and active site-labeled meizothrombin on the membrane surface has also been demonstrated (81). More recently,
the direct involvement of ABE-I of prethrombin-1 (prothrombin
molecule lacking the Gla and Kringle-1 domains) with factor
Va has been demonstrated (34). These latter studies showed
that Arg62 and Lys65 of the B chain of thrombin (Arg67 and
Lys70 chymotrypsin numbering; Refs. 34 and 82) were the
major contributing amino acid residues from ABE-I of prothrombin to prothrombinase activity (34). All these data suggest that a significant conformational transition of the proteinase domain of the prothrombin molecule occurs upon its
interaction with factor Va. It was thus hypothesized that factor
Va may be at least partially responsible for the rearrangement
of the prothrombin structure allowing exposure of hidden or
nonoptimally exposed proteolytic sites required for efficient
substrate catalysis. This extensive molecular rearrangement of
prothrombin for efficient catalysis at Arg320 was also suggested
following the determination of the crystal structure of prethrombin 2 (83). Our data put in the context of the literature
suggest that the extensive binding exosite for prothrombin that
provides for prothrombinase specificity and is responsible for
the correct docking of the substrate in the active site of the
enzyme, is most likely provided by amino acids belonging to
both the carboxyl-terminal portion of factor Va heavy chain and
factor Xa. Complete inhibition of either one separately will
result in the loss of the catalytic efficiency of prothrombinase.

However, it is important to underline that there is not enough
evidence overall to conclude that ABE-I of prothrombin interacts exclusively with the DYDYQ motif from factor Va heavy
chain. It is possible that the extended surface spanning ABE-I
is also responsible for the interaction of the substrate with the
cryptic exosite from factor Xa exposed upon its interaction with
factor Va. Thus, in all cases (i.e. whether ABE-I interacts
exclusively with factor Va heavy chain, exclusively with the
cryptic exosite from factor Xa, or with both), it would appear
that the role of ABE-I in prothrombinase is dependent on the
incorporation of factor Va into the complex as suggested (18,
21, 34). Overall our data underline the importance of factor Va
for the specificity involved in substrate recognition and cleavage by prothrombinase and together with data on record demonstrate that: 1) factor Va binds factor Xa (receptor effect); 2)
following binding a conformational transition of the enzyme
occurs, exposing a portion of the binding exosite(s) for prothrombin (effector effect on factor Xa); and 3) the extended and
contiguous prothrombin binding exosite within prothrombinase is completed by a portion of the heavy chain of the cofactor
(effector effect on prothrombinase). The latter is required to
achieve rates of prothrombin generation observed with prothrombinase. Our data thus define the cofactor, factor Va, as
being the impresario of prothrombinase, orchestrating the spatial rearrangement of substrate and enzyme, which in turn are
necessary for specific and efficient catalysis.
Finally, it is important to note that several studies utilizing
high resolution x-ray crystal structures of coagulation and fibrinolytic enzyme complexes have suggested that, although the
active site geometry of the enzyme component from several
procoagulant and fibrinolytic complexes does not appear to be
altered upon incorporation of the corresponding protein cofactor into the complex, docking of a hidden cleavage site of the
substrate into the active site cleft of the enzyme following
binding of the cofactor molecule to the substrate appeared to
promote enzymatic specificity and optimum catalysis because
the cofactor provided an extended and specific binding surface
for the substrate (84 – 86). Our results are in complete agreement with these findings, and provide for the first time a
functional demonstration for cofactor-directed catalysis of an
enzymatic complex.
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9. Suzuki, K., Dahlbäck, B., and Stenflo, J. (1982) J. Biol. Chem. 257, 6556 – 6564
10. Kane, W. H., and Majerus, P. W. (1981) J. Biol. Chem. 256, 1002–1007
11. Kalafatis, M., and Mann, K. G. (1993) J. Biol. Chem. 268, 27246 –27257
12. Kalafatis, M., Rand, M. D., and Mann, K. G. (1994) J. Biol. Chem. 269,
31869 –31880
13. Mann, K. G., Hockin, M. F., Begin, K. J., and Kalafatis, M. (1997) J. Biol.
Chem. 272, 20678 –20683

Thrombin and Prothrombin Interactive Site on Factor V/Va
14. Guinto, E. R., and Esmon, C. T. (1984) J. Biol. Chem. 259, 13986 –13992
15. Luckow, E. A., Lyons, D. A., Ridgeway, T. M., Esmon, C. T., and Laue, T. M.
(1989) Biochemistry 28, 2348 –2354
16. Rosing, J., Hoekema, L., Nicolaes, G. A., Thomassen, M. L. G. D., Hemker,
H. C., Varadi, K., Schwarz, H. P., and Tans, G. (1995) J. Biol. Chem. 270,
27852–27858
17. Kalafatis, M., Xue, J., Lawler, C. M., and Mann, K. G. (1994) Biochemistry 33,
6538 – 6545
18. Dharmawardana, K. R., and Bock, P. E. (1998) Biochemistry 37, 13143–13152
19. Dharmawardana, K. R., Olson, S. T., and Bock, P. E. (1999) J. Biol. Chem. 274,
18635–18643
20. Anderson, P. J., Nesset, A., Dharmawardana, K. R., and Bock, P. E. (2000)
J. Biol. Chem. 275, 16428 –16434
21. Anderson, P. J., Nesset, A., Dharmawardana, K. R., and Bock, P. E. (2000)
J. Biol. Chem. 275, 16435–16442
22. Esmon, C. T., and Lollar, P. (1996) J. Biol. Chem. 271, 13882–13887
23. Myles, T., Yun, T. H., Hall, S. W., and Leung, L. L. K. (2001) J. Biol. Chem.
276, 25143–25149
24. Verhamme, I. M., Olson, S. T., Tollefsen, D. M., and Bock, P. E. (2002) J. Biol.
Chem. 277, 6788 – 6798
25. Rose, T., and Di Cera, E. (2002) J. Biol. Chem. 277, 18875–18880
26. Pineda, A. O., Cantwell, A. M., Bush, L. A., Rose, T., and Di Cera, E. (2002)
J. Biol. Chem. 277, 32015–32019
27. Wu, Q., Picard, V., Aiach, M., and Sadler, J. E. (1994) J. Biol. Chem. 269,
3725–3730
28. Hofsteenge, J., Taguchi, H., and Stone, S. R. (1986) Biochem. J. 237, 243–251
29. Hofsteenge, J., Braun, P. J., and Stone, S. R. (1988) Biochemistry 27,
2144 –2151
30. Sheehan, J. P., Wu, Q., Tollefsen, D. M., and Sadler, J. E. (1993) J. Biol. Chem.
268, 3639 –3645
31. Liu, L. W., Vu, T. K. H., Esmon, C. T., and Coughlin, S. R. (1991) J. Biol. Chem.
266, 16977–16980
32. Stone, S. R., Braun, P. J., and Hofsteenge, J. (1987) Biochemistry 26,
4617– 4624
33. Stone, S. R., Brown-Luedi, M. L., Rovelli, G., Guidolin, A., McGlynn, E., and
Monard, D. (1994) Biochemistry 33, 7731–7735
34. Chen, L., Yang, L., and Rezaie, A. R. (2003) J. Biol. Chem. 278, 27564 –27569
35. Krishnaswamy, S., and Walker, R. K. (1997) Biochemistry 36, 3319 –3330
36. Wilkens, M., and Krishnaswamy, S. (2002) J. Biol. Chem. 277, 9366 –9374
37. Orcutt, S. J., Pietropaolo, C., and Krishnaswamy, S. (2002) J. Biol. Chem. 278,
46191– 46196
38. Buddai, S. K., Toulokhonova, L., Bergum, P. W., Vlasuk, G. P., and
Krishnaswamy, S. (2002) J. Biol. Chem. 277, 26689 –26698
39. Bianchini, E. P., Louvain, V. B., Marque, P. E., Juliano, M. A., Juliano, L., and
Le Bonniec, B. F. (2002) J. Biol. Chem. 277, 20527–20534
40. Blostein, M. D., Rigby, A. C., Jacobs, M., Furie, B., and Furie, B. C. (2000)
J. Biol. Chem. 275, 38120 –38126
41. Kalafatis, M, and Mann, K. G. (2001) J. Biol. Chem. 276, 18614 –18623
42. Kalafatis, M., and Beck, D. O. (2002) Biochemistry 41, 12715–12728
43. Singh, L. S., Bukys, M. A., Beck, D. O., and Kalafatis, M. (2003) J. Biol. Chem.
278, 28335–28345
44. Camire, R. M., Kalafatis, M., and Tracy, P. B. (1998) Biochemistry 37,
20527–20534
45. Bakker, H. M., Tans, G., Thomassen, C. L. G. D., Yukelson, L. Y., Ebberink, R.,
Hemker, H. C., and Rosing, J. (1994) J. Biol. Chem. 269, 20662–20667
46. Kalafatis, M., Beck, D. O., and Mann, K. G. (2003) J. Biol. Chem. 278,
33550 –33561
47. Pittman, D. D., Tomkinson, K. N., Michnick, D., Selighson, U., and Kaufman,
R. J. (1994) Biochemistry 33, 6952– 6959
48. Marquette, K. A., Pittman, D. D., and Kaufman, R. J. (1995) Blood 86,
3026 –3034
49. Betz, A., and Krishnaswamy, S. (1998) J. Biol. Chem. 273, 10709 –10718
50. Jenny, R. J., Pittman, D. D., Toole, J. J., Kriz, R. W., Aldape, R. A., Hewick,

51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.

3095

R. M., Kaufman, R, J, and Mann, K. G. (1987) Proc. Natl. Acad. Sci. U. S. A.
84, 4846 – 4850
Kalafatis, M., Bertina, R. M., Rand, M. D., and Mann, K. G. (1995) J. Biol.
Chem. 270, 4053– 4057
Kalafatis, M., Haley, P. E., Lu, D., Bertina, R. M., Long, G. L., and Mann, K. G.
(1996) Blood 87, 4695– 4707
van ‘t Veer, C., Golden, N. J., Kalafatis, M., and Mann, K. G. (1997) J. Biol.
Chem. 272, 7983–7994
van ‘t Veer, C., Kalafatis, M., Bertina, R. M., Simioni, P., and Mann, K. G.
(1997) J. Biol. Chem. 272, 20721–20729
Nesheim, M. E., Katzmann, J. A., Tracy, P. B., and Mann, K. G. (1980)
Methods Enzymol. 80, 243–275
Katzmann, J. A., Nesheim, M. E., Hibbard, L. S., and Mann, K. G. (1981) Proc.
Natl. Acad. Sci. U. S. A. 78, 162–166
Barenholz, Y., Gibbs, D., Litmann, B. J., Goll, J., Thompson, T., and Carlson,
D. (1977) Biochemistry 16, 2806 –2910
Gomori, G. (1942) J. Lab. Clin. Med. 27, 955–960
Nesheim, M. E., Prendergast, F. G., and Mann, K. G. (1979) Biochemistry 18,
996 –1003
Laemmli, U. K. (1970) Nature 227, 680 – 685
Towbin, H., Staehlin, T., and Gordon, J. (1979) Proc. Natl. Acad. Sci. U. S. A.
76, 4350 – 4354
Segel, I. H. (1993) pp. 101–160 and 206 –208, John Wiley & Sons, New York
Palmer, T. (1995) pp. 107–152, Prentice Hall/Ellis Horwood, Hemel Hempstead, Hertfordshire, Great Britain
Copeland, R. A. (2000) pp. 266 –291, Wiley-VCH, New York
Monkovic, D. D., and Tracy, P. B. (1990) Biochemistry 29, 1118 –1128
Guinto, E. R., Esmon, C. T., Mann, K., G., and MacGillivray, R. T. A. (1992)
J. Biol. Chem. 267, 2971–2978
Yang, T. L., Cui, J., Rehumtulla, A., Yang, A., Moussalli, M., Kaufman, R. J.,
and Ginsburg, D. (1998) Blood 91, 4593– 4599
Grimm, D. R., Colter, M. B., Braunschweig, M., Alexander, L. J., Neame, P. J.,
and Kim, H. K. W. (2001) Cell. Mol. Life Sci. 58, 148 –159
Michnick, D. A., Pittman, D. D., Wise, R. J., and Kaufman, R. J. (1994) J. Biol.
Chem. 269, 20095–20102
Hortin, G. L., Tollefsen, D. M., and Benuto, B. M. (1989) J. Biol. Chem. 264,
13979 –13982
Hortin, G. L., and Trimpe, B. L. (1991) J. Biol. Chem. 266, 6866 – 6871
Lin, W., Larsen, K., Hortin, G. L., and Roth, J. A. (1992) J. Biol. Chem. 267,
2876 –2879
Hortin, G. L. (1990) Blood 76, 946 –952
Maraganore, J. M., Chao, B., Joseph, M. L., Jablonski, J., and Ramachandran,
K. L. (1989) J. Biol. Chem. 264, 8692– 8698
Huttner, W. B. (1988) Annu. Rev. Physiol. 50, 363–376
Niehrs, C., and Huttner, W. B. (1990) EMBO J. 9, 35– 42
Huttner, W. B., and Baeuerle, P. A. (1988) Mol. Cell. Biol. 6, 97–140
Boskovic, D. S., and Krishnaswamy, S. (2000) J. Biol. Chem. 275, 38561–38570
Monteiro, R. Q., and Zingali, R. B. (2002) Thromb. Haemost. 87, 288 –293
Boskovic, D. S., Giles, A. R., and Nesheim, M. E. (1990) J. Biol. Chem. 265,
10497–10505
Armstrong, S. A., Husten, E. J., Esmon, C. T., and Johnson, A. E. (1990)
J. Biol. Chem. 265, 6210 – 6218
Tsiang, M., Jain, A. K., Dunn, K. E., Rojas, M. E., Leung, L. L. K., and Gibbs,
C. (1995) J. Biol. Chem. 270, 16854 –16863
Vijayalakshmi, J., Padmanabhan, K. P., Mann, K. G., and Tulinsky, A. (1994)
Protein Sci. 3, 2254 –2271
Banner, D. W., D’Arcy, A., Chene, C., Winkler, F. K., Guha, A., Konigsberg,
W. H., Nemerson, Y., and Kirchhofer, D. (1996) Nature 380, 41– 46
Parry, M. A., Fernandez-Catalan, C., Bergner, A., Huber, R., Hopfner, K. P.,
Schlott, B., Guhrs, K. H., and Bode, W. (1998) Nat. Struct. Biol. 5, 917–923
Fuentes-Prior, P., Iwanaga, Y., Huber, R., Pagila, R., Rumennik, G., Seto, M.,
Morser, J., Light, D. R., and Bode, W. (2000) Nature 404, 518 –525

